Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants.
Han CW et al.
Cancers, 2020
CD109: a multifunctional GPI-anchored protein with key roles in tumor progression and physiological homeostasis.
Mii S et al.
Pathology International, 2019
Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
Wu M et al.
The Journal of Biological Chemistry, 2016
Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.
Zannoni GF et al.
Journal of Clinical Pathology, 2016
Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer.
Yu J et al.
Gut, 2015
24951259 (PubMed )
Supplement: gutjnl-2013-306620-s13.pdf
EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features.
Jia X et al.
Contemporary Oncology (poznan, Poland), 2015
Functions of TAp63 and p53 in restraining the development of metastatic cancer.
Tan EH et al.
Oncogene, 2014
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y et al.
International Journal of Clinical and Experimental Pathology, 2013
Select a paper to view details